Protein Fluidics

Executive Summary

Protein Fluidics is a private biotechnology company that develops and commercializes the Pu·MA System, an automated microfluidic platform designed to streamline complex 3D cell model workflows, including immunofluorescence staining, co-cultures, and sequential drug additions for organoids and spheroids. Based in Cambridge, the company targets the growing proteomics and diagnostics markets by providing an open, bench-top automation tool that enhances precision and efficiency in life sciences research, particularly in oncology. The Pu·MA System's proprietary flowchips enable high-reproducibility assays, positioning Protein Fluidics as a key enabler of advanced cell-based studies. The company operates in a rapidly expanding 3D cell culture market, driven by demand for more physiologically relevant models in drug discovery and personalized medicine. With its focus on automation and open-platform design, Protein Fluidics aims to capture market share from traditional manual methods and competing closed systems. While the company has not disclosed funding or valuation, its technology addresses a critical bottleneck in reproducibility and throughput. Near-term growth will likely depend on expanding commercial adoption, securing strategic partnerships, and potentially entering the diagnostics space with IVD-compatible versions of its platform.

Upcoming Catalysts (preview)

• Q4 2026Launch of Next-Generation Pu·MA System with Higher Throughput70% success
• Q2 2027Strategic Partnership with a Major Pharmaceutical Company for Oncology Drug Screening50% success
• TBDFDA 510(k) Clearance for Diagnostic Use of Pu·MA System in Cancer Tissue Analysis30% success